PLASMA/SERUM LEVELS OF FLT3 LIGAND ARE LOW IN NORMAL INDIVIDUALS AND HIGHLY ELEVATED IN PATIENTS WITH FANCONI-ANEMIA AND ACQUIRED APLASTIC-ANEMIA

被引:89
作者
LYMAN, SD
SEABERG, M
HANNA, R
ZAPPONE, J
BRASEL, K
ABKOWITZ, JL
PRCHAL, JT
SCHULTZ, JC
SHAHIDI, NT
机构
[1] UNIV WASHINGTON,DEPT HEMATOL,SEATTLE,WA 98195
[2] UNIV ALABAMA,DEPT MED,DIV HEMATOL ONCOL,BIRMINGHAM,AL 35294
[3] UNIV WISCONSIN,DEPT PEDIAT,DIV PEDIAT HEMATOL ONCOL,MADISON,WI
关键词
D O I
10.1182/blood.V86.11.4091.bloodjournal86114091
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The flt3 ligand is a growth factor that stimulates the proliferation of hematopoietic progenitor and stem cells. We established a sensitive enzyme-linked immunosorbent assay (ELISA) to measure the concentration of flt3 ligand in plasma or serum from normal individuals, as well as in patients with hematopoietic disorders. Concentrations of flt3 ligand in plasma or serum from normal individuals were quite low: only 12% (7 of 60) of normal individuals had flt3 ligand levels above 100 pg/mL (the limit of detection). In contrast, 86% (19 of 22) of samples from patients with Fanconi anemia and 100% (eight of eight) of samples from patients with acquired aplastic anemia had plasma or serum levels above 100 pg/mt. Mean plasma or serum concentrations (calculated by assigning a value of 0 pg/mL to any sample reading below the level of detection) were as follows: normal volunteers, 14 pg/mL; patients with Fanconi anemia, 1,331 pg/mL; and patients with acquired aplastic anemia, 460 pg/mL. Concentrations of flt3 ligand in blood are, therefore, specifically elevated to a level that may be physiologically relevant in hematopoietic disorders with a suspected stem cell component. The elevated flt3 ligand concentrations in these individuals may be part of a compensatory hematopoietic response to boost the level of progenitor cells. (C) 1995 by The American Society of Hematology.
引用
收藏
页码:4091 / 4096
页数:6
相关论文
共 26 条
[1]   ABSENCE OF ABNORMALITIES OF C-KIT OR ITS LIGAND IN 2 PATIENTS WITH DIAMOND-BLACKFAN ANEMIA [J].
ABKOWITZ, JL ;
BROUDY, VC ;
BENNETT, LG ;
ZSEBO, KM ;
MARTIN, FH .
BLOOD, 1992, 79 (01) :25-28
[2]   SERUM STEM-CELL FACTOR CONCENTRATION IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES [J].
BOWEN, D ;
YANCIK, S ;
BENNETT, L ;
CULLIGAN, D ;
RESSER, K .
BRITISH JOURNAL OF HAEMATOLOGY, 1993, 85 (01) :63-66
[3]   STEEL-DICKIE MUTATION ENCODES A C-KIT LIGAND LACKING TRANSMEMBRANE AND CYTOPLASMIC DOMAINS [J].
BRANNAN, CI ;
LYMAN, SD ;
WILLIAMS, DE ;
EISENMAN, J ;
ANDERSON, DM ;
COSMAN, D ;
BEDELL, MA ;
JENKINS, NA ;
COPELAND, NG .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (11) :4671-4674
[4]  
BRASEL K, 1995, LEUKEMIA, V9, P1212
[5]   TRANSMEMBRANE FORM OF THE KIT LIGAND GROWTH-FACTOR IS DETERMINED BY ALTERNATIVE SPLICING AND IS MISSING IN THE SI(D) MUTANT [J].
FLANAGAN, JG ;
CHAN, DC ;
LEDER, P .
CELL, 1991, 64 (05) :1025-1035
[6]  
GALLI SJ, 1994, ADV IMMUNOL, V55, P1
[7]  
HALPERIN DS, 1989, AM J PEDIAT HEMATOL, V11, P380
[8]  
HANAMURA T, 1988, BLOOD, V72, P886
[9]   LIGAND FOR FLT3 FLK2 RECEPTOR TYROSINE KINASE REGULATES GROWTH OF HEMATOPOIETIC STEM-CELLS AND IS ENCODED BY VARIANT RNAS [J].
HANNUM, C ;
CULPEPPER, J ;
CAMPBELL, D ;
MCCLANAHAN, T ;
ZURAWSKI, S ;
BAZAN, JF ;
KASTELEIN, R ;
HUDAK, S ;
WAGNER, J ;
MATTSON, J ;
LUH, J ;
DUDA, G ;
MARTINA, N ;
PETERSON, D ;
MENON, S ;
SHANAFELT, A ;
MUENCH, M ;
KELNER, G ;
NAMIKAWA, R ;
RENNICK, D ;
RONCAROLO, MG ;
ZLOTNIK, A ;
ROSNET, O ;
DUBREUIL, P ;
BIRNBAUM, D ;
LEE, F .
NATURE, 1994, 368 (6472) :643-648
[10]   THE FLT3 LIGAND SUPPORTS PROLIFERATION OF LYMPHOHEMATOPOIETIC PROGENITORS AND EARLY B-LYMPHOID PROGENITORS [J].
HIRAYAMA, F ;
LYMAN, SD ;
CLARK, SC ;
OGAWA, M .
BLOOD, 1995, 85 (07) :1762-1768